Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Constitutional Issues
- Consumer Issues
- Defence
- Economic Development
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Regional Development
- Research and Development
- Science and Technology
- Small Business
- Sports
- Taxation and Finance
- Telecommunications
- Tourism
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry.
- Income Tax Act as it relates to biopharmaceutical products.
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
Legislative Proposal, Bill or Resolution, Regulation
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
Policies or Program
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility".
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
- Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
- Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
- Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership.
- Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
- National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB).
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
- The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
- US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
- World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).
Regulation
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
- New Substances Notification Regulations as it relates to the biopharmaceutical industry.
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
- Smart Regulations as it relates to the biopharmaceutical industry.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Environment Canada
-
Finance Canada (FIN)
-
Fisheries and Oceans Canada (DFO)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Human Resources and Skills Development Canada (HRSDC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Research Council (NRC)
-
Natural Resources Canada (NRCan)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Office of the Information Commissioner of Canada (OIC)
-
Office of the Privacy Commissioner of Canada (OPC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Works and Government Services Canada
-
Senate of Canada
-
Solicitor General Canada (SGC)
-
Statistics Canada (StatCan)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
Government institutions added through a monthly communication report
- Aboriginal Affairs and Northern Development Canada
In-house Corporation Details
Description of activities
Today’s Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets more than 530 pharmaceutical, consumer and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines, women's health and sun care, and is focused on expanding offerings in other areas, including virology, oncology and diabetes.
Based in Montréal, Québec, Merck employs approximately 1250 people across Canada. The Merck Canada manufacturing facility in Québec has been designated by its parent company as a Centre of Excellence for the global production of liquids, ointments and creams. Merck is one of the top R&D investors in Canada, with investments totalling $78.6 million in 2010. For more information about our operations in Canada, visit www.merck.ca.
Responsible officer name and position during the period of this registration
Thomas Cannell,
PRESIDENT
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
16711 TransCanada Highway
Kirkland, QC H9H 3L1
Canada
Telephone number:
514-428-2638
Fax number:
514-428-2662
Parent Company Information
- MERCK FROSST COMPANY
-
1959 Upper Water Street
Suite 900
Halifax, NS B3J 2X2
Canada
Subsidiary Beneficiary Information
Merck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Thomas Cannell,
President |
No public offices held
- Jennifer Chan,
Vice President, Policy & Communications |
No public offices held
- Tama Donoahue-Walker,
Vice President, Patient Access |
No public offices held
- Jeffrey Malawski,
National Manager, Public Health |
No public offices held
- Sandra Wainwright,
Director - Regulatory Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Kathy Armstrong,
Manager, Patient Access - Ontario |
No public offices held
- Christian Blouin,
Director, Public Health & Government Relations |
No public offices held
- Robert Livingston,
Director, Federal Government Affairs |
No public offices held
- Wendy Morton,
Manager, National Policy |
No public offices held
